The stock of Aquestive Therapeutics Inc. (NASDAQ:AQST) increased by $0.18 on Wednesday to $1.71, up 11.76 percent. The last five days have seen an average of 278,442 shares of common stock traded. 19 times new highs were reached in the current year, with a gain of $0.7929. The average number of shares traded over the last 20 days was 209,791, while the average volume over the last 50 days totaled 319,404.
AQST stock dropped -3.40% since last month. On 09/11/23, the company’s shares reached a one-month low of $1.4700. The stock touched a high of $2.69 on 05/23/23, after rallying from a low of $0.72 in 52 weeks. The price of AQST stock has risen by 89.55% or $0.7929 this year, reaching a new high 19 times. Still, the stock price is down -36.43% from the 52-week high.
Valuation Metrics
Beta for the stock is 2.62. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.26, and the price-to-cash flow ratio of 10.93.
Financial Health
For the three months ended June 29, Aquestive Therapeutics Inc.’s quick ratio was 0.90, while its current ratio was 1.00, indicating its inability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 54.20% percent. Aquestive Therapeutics Inc.’s EBITDA margin for the year ended June 29 was -83.22%, whereas its operating margin stood at -61.80% for the same period. Based on annual data, it had gross profit of $28.29 million and revenue of $47.68 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AQST’s return on assets (ROA) during the last 12 months has been -39.80%. There was a 63.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 20.50%.
Earnings Surprise
According to Aquestive Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $13.24 million, while revenues fell by -0.23% to $11.13 million. It was predicted that Aquestive Therapeutics Inc.’s quarterly earnings would be -$0.1, but it ended up being -$0.12, beating the consensus by 16.70%. EBITDA was -$3.86 million for the quarter. At the end of Aquestive Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 163.65 million, while its total debt was $45.12 million. Equity owned by shareholders amounts to $61.73 million.
Technical Picture
Here’s a quick look at Aquestive Therapeutics Inc.’s (AQST) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 56.16%, suggesting the stock is Neutral, with a 76.27% historical volatility rate.
The stochastic %K and %D were 39.25% and 35.83% respectively, while the average true range (ATR) was 0.1223. Based on the 14-day stochastic reading of 72.58%, the RSI (14) reading is 51.24%. On the 9-day MACD Oscillator, the stock is at -0.0078, and the 14-day reading is at -0.0165.
Analyst Ratings
Analysts have assigned Aquestive Therapeutics Inc. (AQST) an Buy rating. AQST is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is AQST’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.00 and $10.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for Aquestive Therapeutics Inc. (AQST) is $6.17.
